Librela is backed by science in every step

Over a decade of development

  • The journey to deliver sustained control of OA pain in dogs began with the proven science of monoclonal antibodies (mAbs), a technology trusted in human medicine since the 1980s2
  • Over 10 years of dedicated veterinary research has led to breakthroughs in adapting this advanced technology for canine OA1

Learn more about the mAb journey.

Go Now

A targeted mechanism of action

  • New scientific knowledge has revealed the important role of nerve growth factor (NGF) as a powerful mediator of OA pain. The targeted mechanism of action of Librela reduces excess NGF caused by OA, reducing pain and neurogenic inflammation3
  • The ability to target this key component of the pain pathway with Librela gives veterinarians another first-line option for providing long-lasting control of OA pain4-6
Anti-NGF mAbs, like Librela, are recommended for first-line management of chronic OA pain in the most up-to-date expert guidelines
   

See how Librela targets OA pain with its unique mechanism of action.

Watch MOA Video

Robust clinical trials and real-world data

  • The safety and efficacy of Librela have been demonstrated in rigorous clinical trials and are continuously supported by pharmacovigilance data7-9
  • Librela has been helping dogs all over the world control their OA pain for 4+ years, and nearly 34 million doses have been delivered globally as of November 20259,10

See what experts are saying about Librela.

Learn More

Transforming lives for dogs and their caregivers

Beyond data, Librela has made a positive impact, renewed mobility, and provided comfort to real canine patients and their caregivers.
  • 90% were extremely or very satisfied with Librela11
  • 97% are likely to recommend Librela11

See the impact Librela has had on real patients.

Explore Success Stories

Dive into real-world data about controlling OA pain with Librela to see the science in every step

What is pharmacovigilance?

Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse events (AEs) after a drug is introduced into the marketplace. Zoetis has a rigorous PV system to collect, verify, evaluate, and report potential adverse events for all Zoetis products. Despite some limitations, when viewed in aggregate, PV data can provide essential information on the safety and efficacy profile of the product.

Benefits

  • Information post-approval is from a broader and more diverse patient population
  • The number of animals treated/exposed to the product is exponentially higher than laboratory and field studies
  • Emerging patterns of AEs can be observed and noted over longer periods of time than the shorter duration of laboratory, clinical, and field studies

Limitations

  • PV data are dependent on voluntary reporting by veterinarians and pet owners; therefore, underreporting occurs
  • PV data are not as well controlled as data gathered in studies
  • PV data can be confounded by comorbidities, underlying pathologic conditions, or concomitant medications not researched with laboratory and field studies
  • Includes extra-label use reports
  • Includes data regardless of causality

Study details9

  • Study was conducted from February 2021 to June 2024
  • More than 18 million doses were sold during the study period
  • The frequency of the most-reported clinical signs were rare or very rare*
  • More than 70% of dogs with adverse events were 10 years old or older†

Pharmacovigilance Study

Explore the full study to see 3-year global experience with Librela.

Download

Study Summary

See the Librela pharmacovigilance study summary.

Download

On-Demand Pharmacovigilance Webinar

Hear from experts on the peer-reviewed pharmacovigilance study (1 CE).

Watch

*“Rare” is 1-10/10,000 treated animals (doses). “Very rare” is <1/10,000 treated animals (doses).
†Dogs ≥10 years of age (12,497). 12,497 of 17,775 total dogs = 70%.

A recent clinical trial was the first to directly compare the efficacy and safety of Librela vs an NSAID (meloxicam) for the control of canine OA pain.12

Meloxicam Comparator Study

Explore the full study that compared Librela vs meloxicam.

Download

Study Summary

View the study summary that compared Librela vs meloxicam.

Download

Explore helpful resources and discover the next
evolution in OA pain management with Librela

Clinician’s Brief Expert Panel: Evolving Approaches to Recognizing & Treating Canine OA

Read how experts approach multi-modal therapy to optimize outcomes for their patients.

Read Now

The Veterinary Roundtable Podcast: Canine Pain, Arthritis, and the Future of Librela

Listen to an open and transparent conversation about Librela among veterinarians with real-world experience with the product.

Listen Now

Librela Global Pharmacovigilance Data Webinar

An on-demand webinar that covers the latest information around canine OA and Librela.

Watch Now

Comparing Librela to the NSAID Meloxicam: A Randomized, Open Label, Multi-Center, Parallel Group Trial

An on-demand webinar that covers the first clinical trial comparing safety and efficacy.

Watch Now

Why Is My Patient Having Trouble Walking? Distinguishing Orthopedic vs Neurologic Causes of Gait Abnormalities

Watch the video and complete the assessment for 1 CE credit.

Start Now

Librela™ is a First-Line Treatment for Canine OA Pain4-6

Watch the video and complete the 5-question assessment for 1 CE credit.

Start Now

Is it OA? Canine Osteoarthritis Exam

Watch a helpful canine orthopedic exam video and download a comprehensive orthopedic exam form to elevate your OA protocol.

Go Now

Advancing OA Pain Education

Sign up to enhance your OA pain treatment protocols and learn OA best practices with this educational email program.

Sign Up

LibrelaVetTeam.com

Explore the official Librela website for veterinary health professionals.

Visit Site

Librela.com

Give pet owners more information about Librela, including success stories.

Visit Site

The Case of Ernest Ham Biscuit: When Bad OA Happens to Good Dogs

A case study exploring monoclonal antibody therapy in the management of osteoarthritis.

Learn More

IMPORTANT SAFETY INFORMATION: Librela is for use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant, or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. Adverse events reported post-approval include ataxia (lack of balance/coordination), anorexia (loss of appetite), lethargy (tiredness), emesis (vomiting), and polydipsia (increased drinking). The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis (skin irritation/inflammation). For complete safety information, refer to the full Prescribing Information at LibrelaPI.com

References: 1. Zoetis data on file. November 2025. 2. Liu JK. The history of monoclonal antibody development - progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116. doi:10.1016/j.amsu.2014.09.001 3. Enomoto M, Mantyh PW, Murrell J, Innes JF, Lascelles BDX. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Vet Rec. 2019;184(1):23. doi:10.1136/vr.1045904. Gruen ME, Lascelles BDX, Colleran E, Gottlieb A, Johnson J, Lotsikas P, et al. 2022 AAHA Pain Management Guidelines for Dogs and Cats. J Am Anim Hosp Assoc. 2022;58(2):55-76. doi:10.5326/JAAHA-MS-7292 5. Cachon T, Frykman O, Innes JF, Lascelles BDX, Okumura M, Sousa P, et al. COAST Development Group's international consensus guidelines for the treatment of canine osteoarthritis. Front Vet Sci. 2023;10:1137888. doi:10.3389/fvets.2023.1137888 6. Monteiro BP, Lascelles BDX, Murrell J, Robertson S, Steagall PVM, Wright B. 2022 WSAVA guidelines for the recognition, assessment and treatment of pain. J Small Anim Pract. 2023;64:177-254. doi:10.1111/jsap.13566 7. Michels GM, Honsberger NA, Walters RR, Tena JKS, Cleaver DM. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Vet Anaesth Analg. 2023;50(5):446-458. doi:10.1016/j.vaa.2023.06.003 8. Corral MJ, Moyaert H, Fernandes T, et al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021;48(6):943-955. doi:10.1016/j.vaa.2021.08.001 9. Monteiro B, Simon T, Knesl O, et al. Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: A case study with bedinvetmab (Librela). Front Vet Sci. 2025;12:1558222. doi:10.3389/fvets.2025.1558222 10. Zoetis data on file. November 2025. 11. ZMR: Canine Osteoarthritis Report Wave 3. May 21, 2025. Zoetis Inc. 12. Innes JF, Lascelles BDX, Bell D, et al. A randomised, parallel group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci. Sec. Anesthesiology and Animal Pain Management. 2025;12. doi:10.3389/fvets.2025.1502218

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2026 Zoetis Services LLC. All rights reserved. LIB-00616R1